News

Two Parkinson’s disease specialists have been named the co-leaders of a New York University movement disorders institute. Drs. Andrew Feigin and Steven J. Frucht are co-executive directors of the Marlene and Paolo Fresco Institute for Parkinson’s and Movement Disorders at the university’s Langone Health Center. “Having two movement disorders…

Rock Steady Boxing is a nonprofit organization that seeks to improve the quality of life of Parkinson’s disease (PD) patients by providing a venue for exercise through noncontact boxing, a concept designed to boost coordination, motor skills, balance, and speech. Researchers have found that Parkinson’s patients who exercise…

Genetic and molecular markers of quicker motor decline in Parkinson’s disease (PD) patients were identified in a computer modeling study of disease progression. Among already described demographic factors, like older age or male sex, the researchers specifically identified a novel and Parkinson’s-specific genetic interaction between the LINGO2 gene and a…

Scientists in Singapore and Korea have discovered a brain mechanism that can trigger Parkinson’s disease symptoms, such as abnormal muscle stiffness, tremors and loss of voluntary movement. The study, which took five years to complete, is titled “Inhibitory Basal Ganglia Inputs Induce Excitatory Motor Signals in the Thalamus.” It was published…

The first patient has been treated in a clinical trial evaluating Titan Pharmaceuticals’ ropinirole implants, designed to treat the signs and symptoms of Parkinson’s disease. The Phase 1/2 study (NCT03250117) is taking place at three clinical sites in the U.S. that specialize in Parkinson’s research. Researchers…

The 3D structure of the PINK1 enzyme, which is linked to the development of early-onset Parkinson’s disease (PD), has finally been identified by researchers at the University of Dundee. The study, titled “Structure of PINK1 and mechanisms of Parkinson’s disease associated mutations,” was published in…

A Phase 1/2 clinical trial evaluating ITI-214 in patients with Parkinson’s disease (PD) has begun enrolling patients, Intra-Cellular Therapies announced. ITI-214 is a potent and selective inhibitor of the phosphodiesterase 1 (PDE1) enzyme, which is involved in the degradation of both cAMP and cGMP (cyclic nucleotides). These are within-cell messengers for…

Researchers at Roche’s innovation center in Basel, Switzerland, have identified four small molecule therapy candidates that target the neurotensin receptor, a protein believed to play a role in the development of Parkinson’s and other neurological disorders. They used a double screening technique to narrow their list from thousands of possibilities…

Carbidopa, a medicine approved for the treatment of Parkinson’s disease, also has shown anti-cancer effects in lab-grown human cells and mice, according to the results of a new study. The findings help explain why cancer incidence usually is lower in Parkinson’s patients — with the exception of skin cancer — and…

Acadia Pharmaceuticals is starting a new Phase 3 clinical trial testing the efficacy of pimavanserin to treat the hallucinations and delusions associated with dementia-related psychosis in a broad array of patients with Parkinson’s, Alzheimer’s, and many other dementias. Pimavanserin, under the brand name Nuplazid, was approved by the U.S. Food and…